Kinnate Biopharma Inc. Quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest in USD from Q4 2019 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
Summary
Kinnate Biopharma Inc. quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest history and growth rate from Q4 2019 to Q4 2023.
  • Kinnate Biopharma Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending December 31, 2023 was $159M, a 28.7% decline year-over-year.
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $159M -$64.1M -28.7% Dec 31, 2023 10-K 2024-03-28
Q4 2022 $223M -$96M -30.1% Dec 31, 2022 10-K 2024-03-28
Q3 2022 $248M -$92.7M -27.2% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $274M -$87.6M -24.2% Jun 30, 2022 10-Q 2022-11-10
Q1 2022 $296M -$82.8M -21.9% Mar 31, 2022 10-Q 2022-11-10
Q4 2021 $319M -$73.8M -18.8% Dec 31, 2021 10-K 2024-03-28
Q3 2021 $341M +$379M Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $361M +$390M Jun 30, 2021 10-Q 2022-11-10
Q1 2021 $379M +$400M Mar 31, 2021 10-Q 2022-11-10
Q4 2020 $393M +$411M Dec 31, 2020 10-K 2023-03-15
Q3 2020 -$38.3M Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$28.5M Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$21.3M Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$17.5M Dec 31, 2019 10-K 2022-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.